Cresilon snagged its second FDA clearance for human use. The FDA granted 510(k) clearance to Traumagel, the startup’s gel that can stop bleeding in just seconds, for temporary external use to control moderate to severe bleeding.
Cresilon, a startup that makes a hemostatic gel to stop bleeding, has raised $25 million in a Series A-4 financing round. The round brings the company's total funding to date to nearly $82 million. The funds will help support Cresilon's entrance into the human health market, as its gel is currently used only by veterinarians.
The home care industry is booming. As Baby Boomers age and more families seek in-home solutions for loved ones, demand for home care services is at an all-time high.
The company will also use the Series C funding from Northwell Health, SoftBank Ventures Korea and others to develop new AI-driven applications for the operating room.
Gauss Surgical, Inc., maker of Triton , a platform for real-time monitoring of surgical blood loss using sponges and a digital platform, just announced the close of its $12.6 million in Series B financing. This brings its total funding to $24.6 million.